{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:44:06Z","timestamp":1789767846774,"version":"4.0.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1053\/j.ackd.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T23:13:44Z","timestamp":1573686824000},"page":"351-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Utilization of Biomarkers in Lupus Nephritis"],"prefix":"10.1053","volume":"26","author":[{"given":"Dawn J.","family":"Caster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1053\/j.ackd.2019.09.001_bib1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ackd.2019.09.001_bib2","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2010050472","article-title":"Updates on the treatment of lupus nephritis","volume":"21","author":"Bomback","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3899\/jrheum.161554","article-title":"Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis","volume":"45","author":"Davidson","year":"2018","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.001_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1053\/j.ackd.2019.09.001_bib7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/ndt\/gfg345","article-title":"Prognosis in proliferative lupus nephritis: the role of socio-economic status and race\/ethnicity","volume":"18","author":"Barr","year":"2003","journal-title":"Nephrolo Dial Transplant"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.001_bib8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.30293","article-title":"Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006","volume":"63","author":"Costenbader","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.02350314","article-title":"ESRD from lupus nephritis in the United States, 1995-2010","volume":"10","author":"Sexton","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ackd.2019.09.001_bib11","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1681\/ASN.2016040415","article-title":"Current and emerging therapies for lupus nephritis","volume":"27","author":"Parikh","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall'Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib15","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/lupus-2017-000213","article-title":"Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?","volume":"4","author":"Ugolini-Lopes","year":"2017","journal-title":"Lupus Sci Med"},{"issue":"10","key":"10.1053\/j.ackd.2019.09.001_bib16","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2215\/CJN.01910213","article-title":"Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis","volume":"8","author":"Olson","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2019.09.001_bib17","first-page":"1495","article-title":"Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus","volume":"30","author":"Mannik","year":"2003","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0961203310379871","article-title":"Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares","volume":"20","author":"Matrat","year":"2011","journal-title":"Lupus"},{"issue":"8","key":"10.1053\/j.ackd.2019.09.001_bib19","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00296-011-1962-3","article-title":"Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4","volume":"32","author":"Julkunen","year":"2012","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/ard.2008.094508","article-title":"Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis","volume":"68","author":"Moroni","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ackd.2019.09.001_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2017.05.025","article-title":"C1q: a fresh look upon an old molecule","volume":"89","author":"Thielens","year":"2017","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0961203314547791","article-title":"Anti-C1q antibodies in systemic lupus erythematosus","volume":"24","author":"Orbai","year":"2015","journal-title":"Lupus"},{"issue":"9","key":"10.1053\/j.ackd.2019.09.001_bib23","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/ndt\/gfs179","article-title":"Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis","volume":"27","author":"Yang","year":"2012","journal-title":"Nephrol Dial, Transplant"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.001_bib24","doi-asserted-by":"crossref","first-page":"e0123572","DOI":"10.1371\/journal.pone.0123572","article-title":"Anti-C1q antibodies as a follow-up marker in SLE patients","volume":"10","author":"Bock","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI200422820","article-title":"Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus","volume":"114","author":"Holers","year":"2004","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2015.06.014","article-title":"Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways","volume":"160","author":"Thanei","year":"2015","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1189\/jlb.3A1215-535R","article-title":"Anti-C1q autoantibodies from patients with systemic lupus erythematosus induce C1q production by macrophages","volume":"101","author":"Thanei","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1172\/JCI200421075","article-title":"Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes","volume":"114","author":"Trouw","year":"2004","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib29","first-page":"1891","article-title":"Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies?","volume":"23","author":"Esdaile","year":"1996","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.001_bib30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0272-6386(12)80609-3","article-title":"Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group","volume":"18","author":"Ricker","year":"1991","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1053\/j.ackd.2019.09.001_bib31","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/1529-0131(200110)44:10<2350::AID-ART398>3.0.CO;2-A","article-title":"A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus","volume":"44","author":"Ho","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib32","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0961203310371154","article-title":"The complex nature of serum C3 and C4 as biomarkers of lupus renal flare","volume":"19","author":"Birmingham","year":"2010","journal-title":"Lupus"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/14397595.2015.1074649","article-title":"Anti-C1q antibody in patients with lupus nephritic flare: 18-month follow-up and a nested case-control study","volume":"26","author":"Fatemi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1053\/j.ackd.2019.09.001_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaut.2015.05.009","article-title":"Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis","volume":"61","author":"Seret","year":"2015","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib35","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s11033-009-9513-7","article-title":"Anti-alpha-actinin antibodies in relation to new-onset systemic lupus erythematosus and lupus nephritis","volume":"37","author":"Zhang","year":"2010","journal-title":"Mol Biol Rep"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.001_bib36","doi-asserted-by":"crossref","first-page":"R162","DOI":"10.1186\/ar2070","article-title":"Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis","volume":"8","author":"Becker-Merok","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib37","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1681\/ASN.2013090987","article-title":"Glomerular autoimmune multicomponents of human lupus nephritis in\u00a0vivo: alpha-enolase and annexin AI","volume":"25","author":"Bruschi","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib38","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1681\/ASN.2009080805","article-title":"Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis","volume":"21","author":"Yung","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"11-12","key":"10.1053\/j.ackd.2019.09.001_bib39","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/prca.201400175","article-title":"Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis","volume":"9","author":"Caster","year":"2015","journal-title":"Proteomics Clin Appl"},{"issue":"8","key":"10.1053\/j.ackd.2019.09.001_bib40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1042\/CS20160732","article-title":"Annexin II-binding immunoglobulins in patients with lupus nephritis and their correlation with disease manifestations","volume":"131","author":"Cheung","year":"2017","journal-title":"Clin Sci (Lond)"},{"issue":"8","key":"10.1053\/j.ackd.2019.09.001_bib41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0961203316678674","article-title":"Anti-heparan sulfate antibody and functional loss of glomerular heparan sulfate proteoglycans in lupus nephritis","volume":"26","author":"Kim","year":"2017","journal-title":"Lupus"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ki.2011.484","article-title":"Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice","volume":"82","author":"Krishnan","year":"2012","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/art.38250","article-title":"Pathogenic mechanisms in lupus nephritis: nucleosomes bind aberrant laminin beta1 with high affinity and colocalize in the electron-dense deposits","volume":"66","author":"Olin","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1053\/j.ackd.2019.09.001_bib44","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard.2007.070482","article-title":"Nucleosomes possess a high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis","volume":"66","author":"Mjelle","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.001_bib45","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1521-4141(200104)31:4<1221::AID-IMMU1221>3.0.CO;2-P","article-title":"Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry","volume":"31","author":"Mostoslavsky","year":"2001","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1053\/j.ackd.2019.09.001_bib46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1258\/ebm.2012.012033","article-title":"The antigen-binding fragment of anti-double-stranded DNA IgG enhances F-actin formation in mesangial cells by binding to alpha-actinin-4","volume":"237","author":"Zou","year":"2012","journal-title":"Exp Biol Med (Maywood)"},{"issue":"12","key":"10.1053\/j.ackd.2019.09.001_bib47","doi-asserted-by":"crossref","first-page":"7704","DOI":"10.4049\/jimmunol.176.12.7704","article-title":"Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin","volume":"176","author":"Zhao","year":"2006","journal-title":"J Immunol"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib48","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4049\/jimmunol.179.2.1313","article-title":"Alpha-actinin immunization elicits anti-chromatin autoimmunity in nonautoimmune mice","volume":"179","author":"Deocharan","year":"2007","journal-title":"J Immunol"},{"issue":"7","key":"10.1053\/j.ackd.2019.09.001_bib49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.autrev.2007.02.001","article-title":"Anti-alpha-actinin antibodies: a new marker of lupus nephritis","volume":"6","author":"Renaudineau","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib50","doi-asserted-by":"crossref","first-page":"R154","DOI":"10.1186\/ar2831","article-title":"Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study","volume":"11","author":"Manson","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.001_bib51","first-page":"272","article-title":"Serum alpha-actinin antibody status in systemic lupus erythematosus and its potential in the diagnosis of lupus nephritis","volume":"7","author":"Babaei","year":"2016","journal-title":"Caspian J Intern Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib52","doi-asserted-by":"crossref","first-page":"E1348","DOI":"10.3390\/ijms19051348","article-title":"Annexin A1 and autoimmunity: from basic science to clinical applications","volume":"19","author":"Bruschi","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1053\/j.ackd.2019.09.001_bib53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.autrev.2011.04.007","article-title":"Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases","volume":"10","author":"Iaccarino","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1053\/j.ackd.2019.09.001_bib54","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.autrev.2015.04.004","article-title":"Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference","volume":"14","author":"Bonanni","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib55","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.3390\/ijms14036259","article-title":"Annexin A2 heterotetramer: structure and function","volume":"14","author":"Bharadwaj","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib56","first-page":"109","article-title":"Autoantibodies specific for alpha-enolase in systemic autoimmune disorders","volume":"27","author":"Pratesi","year":"2000","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1053\/j.ackd.2019.09.001_bib57","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.jprot.2011.05.021","article-title":"Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens","volume":"74","author":"Bruschi","year":"2011","journal-title":"J Proteomics"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10157-016-1235-2","article-title":"Circulating antibodies to alpha-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy","volume":"21","author":"Kimura","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1053\/j.ackd.2019.09.001_bib59","doi-asserted-by":"crossref","first-page":"156795","DOI":"10.1155\/2012\/156795","article-title":"Alpha-enolase, a multifunctional protein: its role on pathophysiological situations","volume":"2012","author":"Diaz-Ramos","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0961203317721752","article-title":"Serum level of anti-alpha-enolase antibody in untreated systemic lupus erythematosus patients correlates with 24-hour urine protein and D-dimer","volume":"27","author":"Li","year":"2018","journal-title":"Lupus"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nrneph.2013.246","article-title":"Lupus nephritis: nucleosomes trapped by aberrantly expressed laminin-beta1","volume":"10","author":"Jones","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12016-010-8204-4","article-title":"Glomerular antibodies in lupus nephritis","volume":"40","author":"Hanrotel-Saliou","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"10.1053\/j.ackd.2019.09.001_bib63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.ki.5002126","article-title":"Glomerular binding of anti-dsDNA autoantibodies: the dispute resolved?","volume":"71","author":"van Bavel","year":"2007","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib64","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/0886022X.2017.1308258","article-title":"Anti-pentraxin 3 auto-antibodies might be protective in lupus nephritis: a large cohort study","volume":"39","author":"Yuan","year":"2017","journal-title":"Ren Fail"},{"issue":"14","key":"10.1053\/j.ackd.2019.09.001_bib65","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1177\/0961203312462267","article-title":"Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis","volume":"21","author":"Doria","year":"2012","journal-title":"Lupus"},{"key":"10.1053\/j.ackd.2019.09.001_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.02.003","article-title":"Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: a comprehensive review","volume":"69","author":"Gatto","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1053\/j.ackd.2019.09.001_bib67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaut.2016.07.002","article-title":"Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB\/NZW F1 mice","volume":"74","author":"Gatto","year":"2016","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.001_bib68","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/apha.12054","article-title":"Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications","volume":"207","author":"Singer","year":"2013","journal-title":"Acta Physiol (Oxf)"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib69","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00467-007-0685-x","article-title":"Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis","volume":"23","author":"Suzuki","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib70","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/rheumatology\/kep468","article-title":"Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis","volume":"49","author":"Rubinstein","year":"2010","journal-title":"Rheumatology. (oxford)"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib71","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12882-017-0678-3","article-title":"Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis","volume":"18","author":"Satirapoj","year":"2017","journal-title":"BMC Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2019.09.001_bib72","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/0961203314526292","article-title":"Estimation of kidney injury molecule-1 (Kim-1) in patients with lupus nephritis","volume":"23","author":"Nozaki","year":"2014","journal-title":"Lupus"},{"key":"10.1053\/j.ackd.2019.09.001_bib73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2017.12.016","article-title":"Inflammation and renal fibrosis: recent developments on key signaling molecules as potential therapeutic targets","volume":"820","author":"Lv","year":"2018","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1053\/j.ackd.2019.09.001_bib74","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1681\/ASN.2006121348","article-title":"Spiegelmer inhibition of CCL2\/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice","volume":"18","author":"Kulkarni","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib75","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1007\/s10067-016-3404-9","article-title":"Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity","volume":"35","author":"Gupta","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib76","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1681\/ASN.2004080658","article-title":"Urine chemokines as biomarkers of human systemic lupus erythematosus activity","volume":"16","author":"Rovin","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib77","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/0961203312452622","article-title":"Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare","volume":"21","author":"Singh","year":"2012","journal-title":"Lupus"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.001_bib78","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00393-016-0109-z","article-title":"Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis","volume":"76","author":"Lee","year":"2017","journal-title":"Z Rheumatol"},{"issue":"10","key":"10.1053\/j.ackd.2019.09.001_bib79","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.4049\/jimmunol.169.10.6020","article-title":"The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells","volume":"169","author":"Kaplan","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib80","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.05.003","article-title":"Role of TWEAK in lupus nephritis: a bench-to-bedside review","volume":"39","author":"Michaelson","year":"2012","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib81","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar2816","article-title":"Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study","volume":"11","author":"Schwartz","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.001_bib82","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/0961203318758507","article-title":"Combined detection of uMCP-1 and uTWEAK for rapid discrimination of severe lupus nephritis","volume":"27","author":"Dong","year":"2018","journal-title":"Lupus"},{"issue":"7","key":"10.1053\/j.ackd.2019.09.001_bib83","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/acr.22762","article-title":"Development of a novel renal activity index of lupus nephritis in children and young adults","volume":"68","author":"Brunner","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1053\/j.ackd.2019.09.001_bib84","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/0961203316684212","article-title":"Prospective validation of a novel renal activity index of lupus nephritis","volume":"26","author":"Gulati","year":"2017","journal-title":"Lupus"},{"issue":"9","key":"10.1053\/j.ackd.2019.09.001_bib85","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0961203316631629","article-title":"Predicting decline of kidney function in lupus nephritis using urine biomarkers","volume":"25","author":"Abulaban","year":"2016","journal-title":"Lupus"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/kisup.2012.25","article-title":"Chapter 12: lupus nephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.001_bib87","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1053\/j.ackd.2019.09.001_bib88","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/art.39623","article-title":"Development of biomarker models to predict outcomes in lupus nephritis","volume":"68","author":"Wolf","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.ackd.2019.09.001_bib89","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3389\/fimmu.2018.02496","article-title":"Monogenic lupus: a developing paradigm of disease","volume":"9","author":"Alperin","year":"2018","journal-title":"Front Immunol"},{"key":"10.1053\/j.ackd.2019.09.001_bib90","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front Immunol"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.001_bib91","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-3083.1999.00664.x","article-title":"The genetics of systemic lupus erythematosus","volume":"50","author":"Lindqvist","year":"1999","journal-title":"Scand J Immunol"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib92","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semnephrol.2015.08.002","article-title":"Genetics of lupus nephritis: clinical implications","volume":"35","author":"Munroe","year":"2015","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ackd.2019.09.001_bib93","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clim.2016.09.012","article-title":"Genetics of human lupus nephritis","volume":"185","author":"Iwamoto","year":"2017","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib94","first-page":"415","article-title":"Role of interferons in SLE. Best practice & research","volume":"31","author":"Bengtsson","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib95","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semnephrol.2015.08.003","article-title":"Neutrophils, dendritic cells, toll-like receptors, and interferon-alpha in lupus nephritis","volume":"35","author":"Lorenz","year":"2015","journal-title":"Semin Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib96","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.mnh.0000444816.57378.21","article-title":"Lupus nephritis: update on mechanisms of systemic autoimmunity and kidney immunopathology","volume":"23","author":"Lorenz","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ackd.2019.09.001_bib97","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/DDDT.S170969","article-title":"Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date","volume":"13","author":"Felten","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib98","doi-asserted-by":"crossref","first-page":"e000080","DOI":"10.1136\/lupus-2014-000080","article-title":"Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE","volume":"2","author":"Kennedy","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib99","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib100","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0961203309105529","article-title":"Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus","volume":"18","author":"Petri","year":"2009","journal-title":"Lupus"},{"issue":"Suppl 1","key":"10.1053\/j.ackd.2019.09.001_bib101","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/ar2887","article-title":"Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN\u03b1 antibody, in systemic lupus erythematosus","volume":"12","author":"Yao","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib102","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib103","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib104","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.001_bib105","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ki.1984.75","article-title":"Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome","volume":"25","author":"Austin","year":"1984","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.001_bib106","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.001_bib107","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/BOR.0000000000000577","article-title":"Neutrophils in lupus nephritis","volume":"31","author":"Nishi","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib108","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.it.2009.07.011","article-title":"NETs: a new strategy for using old weapons","volume":"30","author":"Papayannopoulos","year":"2009","journal-title":"Trends Immunology"},{"issue":"73","key":"10.1053\/j.ackd.2019.09.001_bib109","doi-asserted-by":"crossref","first-page":"73ps79","DOI":"10.1126\/scitranslmed.3002138","article-title":"Dissecting the immune cell mayhem that drives lupus pathogenesis","volume":"3","author":"Craft","year":"2011","journal-title":"Sci Transl Med"},{"issue":"73","key":"10.1053\/j.ackd.2019.09.001_bib110","doi-asserted-by":"crossref","first-page":"73ra20","DOI":"10.1126\/scitranslmed.3001201","article-title":"Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus","volume":"3","author":"Garcia-Romo","year":"2011","journal-title":"Sci Transl Med"},{"issue":"73","key":"10.1053\/j.ackd.2019.09.001_bib111","doi-asserted-by":"crossref","first-page":"73ra19","DOI":"10.1126\/scitranslmed.3001180","article-title":"Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus","volume":"3","author":"Lande","year":"2011","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.001_bib112","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J Immunol"},{"issue":"7","key":"10.1053\/j.ackd.2019.09.001_bib113","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.4049\/jimmunol.1103414","article-title":"T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses","volume":"188","author":"Tillack","year":"2012","journal-title":"J Immunol"},{"issue":"21","key":"10.1053\/j.ackd.2019.09.001_bib114","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.001_bib115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00281-013-0375-7","article-title":"Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity","volume":"35","author":"Carmona-Rivera","year":"2013","journal-title":"Semin Immunopathol"},{"issue":"7","key":"10.1053\/j.ackd.2019.09.001_bib116","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/annrheumdis-2018-214620","article-title":"Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus","volume":"78","author":"Rahman","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib117","first-page":"477","article-title":"Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis","volume":"56","author":"Jourde-Chiche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.001_bib118","doi-asserted-by":"crossref","first-page":"e0196117","DOI":"10.1371\/journal.pone.0196117","article-title":"Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: clinical\/pathologic associations and etiologic mechanisms","volume":"13","author":"Wither","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib119","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"issue":"suppl_1","key":"10.1053\/j.ackd.2019.09.001_bib120","doi-asserted-by":"crossref","first-page":"i71","DOI":"10.1093\/ndt\/gfw300","article-title":"Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise","volume":"32","author":"Birmingham","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.ackd.2019.09.001_bib121","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/art.22008","article-title":"Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus","volume":"54","author":"Brunner","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.001_bib122","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.autrev.2007.11.013","article-title":"The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)\/Lipocalin-2 as a biomarker for lupus nephritis","volume":"7","author":"Rubinstein","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1053\/j.ackd.2019.09.001_bib123","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1177\/0961203318788167","article-title":"Composite urinary biomarkers to predict pathological tubulointerstitial lesions in lupus nephritis","volume":"27","author":"Ding","year":"2018","journal-title":"Lupus"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154855951930165X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154855951930165X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:01:47Z","timestamp":1761548507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154855951930165X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":123,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S154855951930165X"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.09.001","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of Biomarkers in Lupus Nephritis","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}